Physiologist discover a new disease affecting neuromusculartransmission at the neuromuscular junction NMJ. They called thecondition PLT disease and it causes weakness and increasing fatiguein the skeletal muscles, due to the production of antibodies thattarget membrane bound receptors of the skeletal muscle cells
Part A
How will the antibodies produced in PLT disease affectneuromuscular transmission? Identify the specific receptors on theskeletal muscle cells that will target these antibodies and theneurotransmitters involved
Part B
The physiologists decide to treat the PLT disease with a classof drug that enhances cholinergic transmission at the neuromuscularjunction.
Explain why enhancing the cholinergic transmission at the NMJ isa suitable treatment for PLT disease which causes skeletal muscleweakness.
Response should include detailed explanation of the eventsinvolved in cholinergic transmission, the role of cholinesterase innormal NMJ physiology, specific action of anticholinesterases oncholinesterase, and how anticholinesterase will affect skeletalmuscle contraction.
